Anzor Pharmaceuticals Licenses Key Fibroblast Growth Factor Technology From New York University
FGF TECHNOLOGY REPRESENTS MAJOR BREAKTHROUGH IN METABOLIC AND CANCER DISEASES BOSTON, February 25, 2025 – Anzor Pharmaceuticals, a leader in the development of targeted fibroblast growth factor (FGF) peptide therapy, today announced an exclusive worldwide license for FGF technology developed by Dr. Moosa Mohammadi, Ph.D., the company’s Chief Scientific Officer, who was previously a Professor […]
